TNXP$13.98
$13.95
Chart
Performance
Key Stats
AI TNXP Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldTonix Pharmaceuticals Holding Corp. (TNXP) presents a mixed investment profile. While its focus on therapeutics for various diseases and a pipeline of product candidates offer thematic potential, its financial performance, characterized by significant net losses and negative revenue for several periods, coupled with a weak technical outlook, suggests a cautious approach. Investors should consider the high risk associated with the biopharmaceutical sector and the company's current stage of development.
Thematic
Tonix Pharmaceuticals operates in the biopharmaceutical sector, a field with inherent growth potential driven by advancements in healthcare, an aging population, and unmet medical needs. The company's focus on CNS disorders, immunology, infectious diseases, and rare diseases addresses significant market opportunities. However, the success of its product pipeline is heavily dependent on clinical trial outcomes and regulatory approvals, which are inherently uncertain.
Fundamental
Tonix Pharmaceuticals exhibits significant financial challenges. The company has consistently reported substantial net losses, has minimal to no revenue in recent historical periods, and negative EPS estimates. While it holds a significant amount of cash, its operational expenses and burn rate are high, leading to negative free cash flow. The lack of profitability and revenue makes traditional valuation metrics like P/E less meaningful.
Technical
The technical indicators for Tonix Pharmaceuticals show a predominantly bearish sentiment. The stock price has declined significantly over the past year and is trading well below its 52-week high. Most short-term and long-term moving averages suggest a downward trend, and key oscillators are mixed but lean towards caution or selling pressure.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 60 |
| Targeted Disease Areas | 70 |
| Commercialization Progress | 40 |
| Partnerships and Collaborations | 50 |
| Biotech Sector Volatility | 40 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 10 |
| Growth | 30 |
| Balance Sheet Health | 70 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 30 |
| Oscillators (Specific) | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Positive Earnings Surprise
Recent EPS surprise of 12.07% indicates the company is exceeding analyst expectations, suggesting potential for stock price appreciation.
Improving Cash Position
Cash equivalents have increased from $24.95M in Q4 2023 to $98.78M in Q4 2024, indicating enhanced liquidity and financial stability.
Bearish Points (10)
Significant Net Losses
The company has reported substantial net losses in recent periods (e.g., Net Income of -$130.04M in 2024), indicating a lack of profitability and potential financial strain.
Negative Net Margins
Net margins are deeply negative (e.g., -1288.3% in 2024), highlighting severe inefficiency in converting revenue into profit.
Calendar
November 2019
1
Next Dividend Date
August 2025
15
Next Earnings Date
H: $-1.88
A: $-1.88
L: $-1.88
H: 2.70M
A: 2.60M
L: 2.50M
Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.
Seasonals
Price Target
61.67 USD
The 39 analysts offering 1 year price forecasts for TNXP have a max estimate of 70.00 and a min estimate of 50.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor and peer in poxvirus vaccine development (Jynneos vs. TNX-801/TNX-1800), a key focus area for TNXP in biodefense.
Weight: 90
Major biodefense company with a focus on public health threats, including anthrax and smallpox vaccines (ACAM2000), overlapping with TNXP's infectious disease and biodefense pipeline.
Weight: 88
Clinical-stage biopharmaceutical company with a pipeline focused on central nervous system (CNS) disorders, including depression and narcolepsy, directly competing with TNXP's CNS efforts.
Weight: 85
Biopharmaceutical company specializing in brain health with a focus on CNS disorders, particularly depression and neurological conditions, aligning with TNXP's CNS pipeline.